Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 8, 2013, Pages 635-644

  Llibre, Josep M ^a,b   Revollo, Boris ^a   Vanegas, Samuel ^c   Lopez Nuñez, Juan J ^a   Ornelas, Arelly ^d   Marin, Joan M ^a   Santos, Jose R ^b   Marte, Paola ^a   Morera, Marta ^a   Zuluaga, Paola ^a   Tor, Jordi ^a   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Lluita Contra la SIDA Foundation   (Spain)

^c Fundacion Carolina   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

AIDS; HAART; Mortality; Opportunistic infections; Pneumocystis jirovecii; Pneumonia

Indexed keywords

ADULT; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLUS; CD4 LYMPHOCYTE COUNT; CORRELATIONAL STUDY; CYTOMEGALOVIRUS INFECTION; DEVELOPED COUNTRY; FEMALE; FOLLOW UP; HERPES SIMPLEX VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENSIVE CARE UNIT; KAPOSI SARCOMA; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PNEUMOCYSTIS PNEUMONIA; RETROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPED COUNTRIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84880286125     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2013.777778     Document Type: Article

References (25)

1. K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, et al. AIDS-defi ning opportunistic illnesses in US patients, 1994-2007:a cohort study. AIDS 2010; 24:1549-59.
2. Ndiaye B, Ould-Kaci K, Salleron J, Bataille P, Bonnevie F, Cochonat K, et al. Characteristics of and outcomes in HIVinfected patients who return to care after loss to follow-up. AIDS 2009;23:1786-9.
3. Teshale EH, Hanson DL, Wolfe MI, Brooks JT, Kaplan JE, Bort Z, et al. Reasons for lack of appropriate receipt of primary Pneumocystis jiroveci pneumonia prophylaxis among HIV-infected persons receiving treatment in the United States: 1994-2003. Clin Infect Dis 2007;44 :879-83. (Pubitemid 46365318)
4. Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, et al. Late presentation of HIV infection: a consensus defi nition. HIV Med 2011;12:61-4.
5. Lodwick R K, Sabin C A, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010;376:340-5.
6. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, et al. Late presentation for human immunodefi-ciency virus care in the United States and Canada. Clin Infect Dis 2010;50:1512-20.
7. US Department of Health and Human Services. Healthy People 2010: understanding and improving health. 2 nd ed. DHHS
8. Hurley L, Klein D, Silverberg M, Quesenberry C, Mugavero M. Early missed offi ce visits post-HIV diagnosis and mortality in a large healthcare system. Abstract 1129. 19 th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, March 5-8, 2012.
9. Cohen M S, Chen Y Q, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEngl J Med 2011;365:493-505.
10. HIV treatment as prevention-i t works. Lancet 2011, 377, 1719
11. El-Sadr WM, Coburn B J, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS 2011;25:2295-9.
12. Kitahata MM, Gange S J, Abraham A G, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. NEngl J Med 2009;360:1815-26.
13. Brooks JT, Kaplan JE, Holmes KK, Benson C, Pau A, Masur H. HIV-associated opportunistic infections-going, going, but not gone: the continued need for prevention and treatment guidelines. Clin Infect Dis 2009;48:609-11.
14. Hull MW, Phillips P, Montaner JS. Changing global epidemiology of pulmonary manifestations of HIV/AIDS. Chest 2008;134:1287-98.
15. Morris A, Lundgren J D, Masur H, Walzer P D, Hanson D L, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004;10:1713-20. (Pubitemid 39319360)
16. Miller R F, Evans H E, Copas AJ, Huggett J F, Edwards S G, Walzer PD. Seasonal variation in mortality of Pneumocystis jirovecii pneumonia in HIV-infected patients. Int J STD AIDS 2010;21:497-503.
17. Walzer PD, Evans H E, Copas A J, Edwards SG, Grant A D, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008;46:625-33. (Pubitemid 351263506)
18. From the Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. JAMA 1992;267:2294-9.
19. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9.
20. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300:51-9. (Pubitemid 351920404)
21. Gill V S, Lima V D, Zhang W, Wynhoven B, Yip B, Hogg RS, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010;50:98-105.
22. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21:685-92. (Pubitemid 46568625)
23. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575.
24. Hamers FF, Downs AM. The changing face of the HIV epidemic in Western Europe: what are the implications for public health policies? Lancet , 2004, 364, 83-94 (Pubitemid 38968629)
25. Levy I, Mor Z, Anis E, Maayan S, Leshem E, Pollack S, et al. Men who have sex with men, risk behavior, and HIV infection: integrative analysis of clinical, epidemiological, and laboratory databases. Clin Infect Dis 2011;52:1363-70.